Press release content from Accesswire. The AP news staff was not involved in its creation.
AMPD CEO Provides Corporate Update and Outlook for Q1 2021
February 4, 2021 GMT
VANCOUVER, BC / ACCESSWIRE / February 4, 2021 / AMPD Ventures Inc. (“AMPD” or the “Company”) (CSE:AMPD)(FRA:2Q0), is pleased to provide its first quarterly update of the new year, providing an update on the progress made during 2020, as well as some glimpses into what the Company sees ahead in 2021.
AMPD is building the next generation of digital infrastructure with its “High Performance Computing at the Edge” platform. AMPD’s approach provides the increased performance and reduced latency required for applications such as virtual production, volumetric capture, animation and visual effects, multiplayer video games including eSports, artificial intelligence, mixed reality, and high-level academic research.
Microsoft, NPower launching accelerator to equip underrepresented youth for digital careers
The Canadian government and Canada s Digital Technology Supercluster are investing a combined $8.7 million in the program
Canada’s Digital Technology Supercluster, a cross-industry collaboration of some of Canada’s biggest names in technology, communications, healthcare and more, announced an investment in the Canadian Tech Talent Accelerator project to provide in-demand technology skills to young Canadians.
The Digital Supercluster includes companies like Microsoft, TELUS, LifeLabs and more. A full list can be found here.
The accelerator will receive a total investment of $8.7 million, which includes $7.3 million from the industry and $1.4 million from the Candian government. Additionally, NPower Canada, a workforce development initiative, will collaborate with Microsoft Canada and Blueprint to launch the Tech Talent Accelerator.
Share this article
Supporting Canada s economic recovery by providing in-demand tech skills to Canadians
VANCOUVER, BC, Jan. 28, 2021 /CNW/ - Canada s Digital Technology Supercluster ( Digital Supercluster ) is proud to announce its largest investment to date in developing in-demand digital talent through its Capacity Building Program. The Canadian Tech Talent Accelerator project is a total investment of $8.7 million, with $7.3 million invested by industry and other partners and $1.4 million of co-investment by the Government of Canada s Innovation, Science and Industry through the Digital Supercluster. This project supports Canada s future by providing in-demand technology skills to young Canadians underrepresented in our economy, preparing them for the digital workforce and supporting Canada s economic recovery.
Posted on 250
Canexia Health today announced critical progress milestones as well as new partnerships for Project ACTT (Access to Cancer Testing & Treatment in Response to COVID-19). With a strategic investment from Canada’s Digital Technology Supercluster, Project ACTT is speeding up cancer testing for targeted treatment selection during the pandemic through a minimally invasive circulating tumor (ctDNA) DNA test, which is available as an alternative to some surgical tissue biopsies for patients with advanced lung, breast, or colorectal cancer.
Milestones to date include:
Reportable findings were identified for almost 50 percent of samples.
The program has expanded across Canada with samples received from Nova Scotia, New Brunswick, Quebec, Ontario, Saskatchewan, Alberta, and British Columbia.
Vector Institute. It leverages past work of partners to address needs of infectious disease research with guidance from domain experts. We are very proud to contribute to such an important effort in Canada, as it will have an impact not only on Canadian s healthcare but on COVID-19 patients around the world, as we learn more about the disease and ways we can treat patients with it, said George N. Nikopoulos, President and CEO of Mannin Research Inc.
For more information, visit
About Mannin Research Inc.
Mannin Research is a research-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class therapeutics for vascular diseases. Mannin Research main platform is built on the expertise in activation of Angiopoietin-Tie2 signalling pathway, a major regulator of vascular endothelium with a broad range of therapeutic applications.